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BACKGROUND: Bone metastases are associated with a worse outcome in patients with neuroendocrine tumours (NETs). Tumour
overexpression of C-X-C chemokine receptor 4 (CXCR4) appears predictive of skeletal involvement. We investigated the role of
circulating tumour cells (CTCs) and CXCR4 expression on CTCs as potential predictors of skeleton invasion.
METHODS: Blood from patients with metastatic bronchial, midgut or pancreatic NET (pNET) was analysed by CellSearch. CXCR4
immunohistochemistry was performed on matched formalin-ﬁxed parafﬁn-embedded (FFPE) samples.
RESULTS: Two hundred and ﬁfty-four patients were recruited with 121 midgut and 119 pNETs, of which 51 and 36% had detectable
CTCs, respectively. Bone metastases were reported in 30% of midgut and 23% of pNET patients and were signiﬁcantly associated
with CTC presence (p= 0.003 and p < 0.0001). In a subgroup of 40 patients, 85% patients with CTCs had CTCs positive for CXCR4
expression. The proportion of CXCR4-positive CTCs in patients with bone metastases was 56% compared to 35% in those without
(p= 0.18) it. Staining for CXCR4 on matched FFPE tissue showed a trend towards a correlation with CXCR4 expression on CTCs (p=
0.08).
CONCLUSIONS: CTC presence is associated with bone metastases in NETs. CXCR4 may be involved in CTC osteotropism and
present a therapeutic target to reduce skeletal morbidity.
British Journal of Cancer (2019) 120:294–300; https://doi.org/10.1038/s41416-018-0367-4
INTRODUCTION
Neuroendocrine tumours (NETs) are a heterogeneous group of
malignancies with diverse biological and clinical features.
Although NETs may develop in almost all organs, they are
prevalent within the lung, pancreas and gastrointestinal tract, and
their incidence has markedly increased over the last four
decades.1 The presence of bone metastases has been described
in up to 32% of patients with NETs and is associated with a worse
clinical outcome.2,3 The molecular mechanisms underlying the
formation of skeletal metastases in NETs are not well understood,
but the overexpression of C-X-C chemokine receptor type 4
(CXCR4) in primary tumours appears highly predictive of skeletal
metastases.4
The CXCL12/CXCR4 axis is a critical molecular determinant in
the bone homing of hematopoietic stem cells during foetal life
and marrow transplantation.5 On the basis of the hematopoietic
model, several authors have hypothesised that prostate and
breast cancer cells may use a similar pathway to localise to the
bone marrow.6,7 The functional role of the CXCL12/CXCR4 axis in
NETs has recently been investigated. CXCR4 is overexpressed in
gastro-entero-pancreatic and lung NETs where it signals through
the mammalian target of rapamycin (mTOR) pathway inducing
uncontrolled cell growth. Expression of CXCR4 is positively
associated with a higher grade and poor patient outcome but
has an inverse correlation with somatostatin receptor expres-
sion.8–10 Moreover, CXCR4 expression is upregulated by hypoxia,
and its agonist stimulation activates the mitogen-activated protein
kinase (MAPK) p42/44 signalling pathway, increasing ileal carci-
noid cell migration.11 Novel ﬁndings on the functional role of the
CXCL12/CXCR4 axis in modulating the osteotropism of NETs come
from recent in vitro experimental models suggesting that CXCL12
conveys epithelial-mesenchymal transitions (EMT) promoting
signals in NET cells through CXCR4, which in turn regulates
transcriptional, morphological and functional modiﬁcations result-
ing in enhanced osteotropism of NET cells.12
The isolation and analysis of circulating tumour cells (CTCs) from
the blood of patients with cancer offers the opportunity to
investigate and understand the biology of metastatic process.
Using the CellSearch system we have previously demonstrated
that CTCs are detectable in patients with NET and that their
presence is an adverse prognostic factor.13,14 In addition, we have
shown that early changes in CTC numbers predict survival in
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response to therapy15 and that therapeutic targets such as the
somatostatin receptor can be detected on CTCs.16 A recent work
suggests that CTC count can be used as an early predictor of bone
metastatic potential in prostate,17 breast18 and lung cancer.19 In
addition, the analysis of C-X-C chemokine receptor 4 (CXCR4)
expression on CTCs is feasible and has been performed in small
cell lung cancer patients in whom CXCR4 overexpression was
shown to be predictive of shorter progression-free survival.20
Here we investigate the role of CTCs as a marker of bone
metastases in a large cohort of NET patients and evaluate the
expression of CXCR4 on CTCs as a potential predictor of skeletal
invasion.
MATERIALS AND METHODS
CTC enumeration in NET patients
To be eligible for the study, patients had to be ≥ 18 years of age
and had to have a histologically conﬁrmed midgut, pancreatic or
bronchial NET with metastatic disease. Patients who had under-
gone systemic anti-cancer therapy or embolization within the
previous month were excluded while patients receiving long-term
somatostatin analogues (SSAs) were included. Data were collected
depending on age, gender, primary site, WHO grade (according to
Ki67 proliferation index), metastatic sites and previous treatments.
The study was approved by the Central Ethics Committee (IRAS
ref. 13/LO/0376) and performed in accordance with the Declaration
of Helsinki. All patients provided written informed consent.
Patients provided 7.5 mL of blood samples, which were collected
into CellSave tubes (Janssen Diagnostics, Raritan, NJ, USA),
maintained at room temperature and processed within 96 h of
collection. The CellSearch platform was used for the detection and
enumeration of CTCs as previously described.13 Brieﬂy, this semi-
automated system enriches CTCs by EpCAM-targeted immuno-
magnetic selection, following which the CTCs are identiﬁed by
positive immunoﬂuorescent staining for pan-cytokeratin and DAPI,
and negative staining for the leucocyte marker CD45.
Detection of CXCR4 expression using CellSearch
In order to develop the assay for CXCR4 detection using the
CellSearch platform, the pancreatic NET (pNET) cell line BON1 was
used. This has previously been reported to express both EpCAM
and CXCR4.12 Five hundred BON1 cells were spiked into 7.5 mL of
healthy donor blood collected in CellSave preservative tubes and
processed through the CellSearch platform. A ﬂuorescein-
conjugated antibody can be added for detection by the fourth
ﬂuorescence channel to further characterise the cells for an
additional marker of interest. For this study, the AF488-conjugated
anti-CXCR4 antibody [UMB2, Abcam, Ab208128] was used and
cells were deﬁned as positive for CXCR4 expression when staining
was present in the fourth channel (Fig. 1a, b). Patient samples
were analysed using the protocol optimised on cells (antibody
concentration 1:10 and exposure time 5 s), and evaluations
regarding the expression of CXCR4 on CTCs were made by two
independent operators having no knowledge of the clinical status
of the patients.
Immunohistochemistry
Three-micron-thick formalin-ﬁxed parafﬁn-embedded (FFPE) tis-
sue sections of normal human tonsil, placenta and neuroendo-
crine tumours were subjected to conventional single
immunohistochemistry (IHC) to study the expression of CXCR4
using a rabbit monoclonal anti-CXCR4 antibody [UMB2, Abcam,
Ab124824]. Human tonsil and placenta tissues were used as the
positive control tissue to deﬁne the optimal staining protocol, and
a dilution of 1:50 was found to result in a speciﬁc staining pattern
in the absence of a background signal. Parallel tests without the
primary antibody served as the negative control. Immunostaining
was performed using the automated BOND-III Autostainer (Leica
Microsystems, UK) according to protocols described elsewhere.21
The semi-quantitative analysis of the stained sections was
performed by an expert pathologist having no knowledge of
the pathological data using a Nikon Eclipse E400 microscope.
Immunoreactivity was quantiﬁed in terms of the percentage of
positive tumour cells and staining intensity.
Statistical analysis
Descriptive statistics was used for patient demographics as well as
for clinical and pathological data. Receiver operating characteristic
(ROC) curve analysis was used to set the optimal cut-off for CTCs
to predict bone colonisation. The association between CTCs and
clinicopathological features including grade and sites of metas-
tases was evaluated by Fisher’s test and chi-square test, while the
Spearman’s test was used to test the correlation between CXCR4
expression on CTCs and tumour tissue. A multivariable logistic
regression model with backward stepwise elimination was used to
adjust for confounders. All tests were two-sided, and statistical
signiﬁcance was declared at p ≤ 0.05. Statistical analysis was
conducted using GraphPad Prism 5 software (GraphPad Software,
L Jolla, CA, USA) and MedCalc 12.7 (MedCalc Software bvba,
Ostend, Belgium).
RESULTS
Between 2009 and 2017, a total of 254 patients with metastatic
NETs were recruited from the Royal Free Hospital, London, which
include 119 patients with pNET, 121 patients with midgut NET and
14 patients with bronchial NET. Baseline characteristics are listed
in Table 1. Pancreatic and midgut NETs represented the biggest
subgroups (47 and 48% of patients, respectively). The majority of
patients had grade-1 (39%) or -2 tumours (47%), with only 13%
having grade-3 tumours. Of the 33 patients with G3 tumours, 20
patients had well-differentiated (WD) and 10 had poorly
differentiated (PD) tumours. This information was not available
for the remaining three patients. Almost all the patients had liver
metastases (96%). Skeletal involvement was detected in 28% of
patients and was more commonly observed in tumours arising
from the lung (64%), compared with gastro-entero-pancreatic
NETs (26%). At the time of enrolment, 27% of patients were
treatment naive, 29% were receiving SSAs at the time of sampling
and 43% had received alternative anti-cancer treatments in
addition to, or instead of, SSAs. For the ﬁnal group, the shortest
time between the last treatment and CTC sampling was 1 month,
with a median time of 13 months (ranging from 1 to 97 months).
CTC count in relation to bone colonisation
A CTC count of ≥ 1 was used for the initial exploratory analysis,
since this threshold has been previously deﬁned as the optimum
threshold for prognostication.14 The association between CTC
presence and grade, previous treatment and sites of metastases is
shown in Table 2. Liver involvement has not been included in the
correlation analysis, since 96% of the patients had liver
metastases, and neither the bronchial NETs due to its low number.
There was a signiﬁcant association between CTC presence and
grade in both pancreatic (p= 0.0193) and midgut (p= 0.0009)
NETs, but there was no correlation between CTC presence and
treatment in either pancreatic (p= 0.134) or midgut (p= 0.1418)
NET. Of patients with metastatic pNET, 36% had detectable CTCs
with a mean of 11 CTCs per 7.5 mL of blood (range 0–430, SD 53).
Bone metastases were identiﬁed in 27 pNET patients (23%) by CT
scan (59%), Ga68 PET-CT (41%), MRI (26%), Octreoscan (22%), FDG
PET-CT (15%) and bone scan (11%). For 89% of patients imaging
was performed within 3 months from enrolment. Applying the
presence or absence of CTCs as a dichotomous variable, there was
a signiﬁcant association between bone metastases and CTC
presence (p < 0.0001). There was no association between lung,
peritoneal or lymph node metastases and CTC presence. To
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identify the optimal cut-off number of CTCs capable of predicting
bone colonisation, ROC curve analysis was performed (Supple-
mentary Figure S1).
In the pNET cohort, a CTC count of ≥ 2 distinguished between
patients with and without bone metastases with a sensitivity of
66.7% (95% CI= 46–83.5%) and a speciﬁcity of 88% (95% CI=
79.6–93.9%), with an Area Under the Curve of 0.79 (95% CI=
0.7–0.86, p= 0.0001). Positive predictive value (PPV) and
negative predictive value (NPV) for the deﬁned cut-off were
62.1% (95% CI= 41.9–79.6%) and 90% (95% CI= 81.9–95.3%),
respectively. By univariate analysis, a number of CTCs of ≥
2 signiﬁcantly predicted bone colonisation (p < 0.0001) (Supple-
mentary Table S1). By logistic regression analysis, including the
presence of at least two CTCs as a dependent variable and
treatment, grade, lung, peritoneal, bone and lymph node
metastases as independent variables, the association between
bone metastases and CTCs was conﬁrmed (p < 0.0001) and was
not independent from grade.
Of patients with midgut tumours, 51% had detectable CTCs
with a mean number of 15 (range 0–636, SD 66). Bone metastases
were identiﬁed in 36 midgut patients (30%) by CT scan (44%),
Ga68 PET-CT (42%), Octreoscan (42%), MRI (22%), FDG PET-CT
(11%) and bone scan (3%). For 78% of patients imaging was
performed within 3 months from enrolment. There was a
signiﬁcant association between bone metastases and CTC
presence (p= 0.003). There was no association between lung,
peritoneal or lymph node metastases and CTC presence. In the
midgut cohort, the ROC curve analysis showed that a CTC count
of ≥ 1 was able to distinguish between patients with and without
bone metastases with a sensitivity of 72.2% (95% CI= 54.8–85.8%)
and a speciﬁcity of 57.6% (95% CI= 46.4–68.3%), with an AUC of
0.65 (95% CI= 0.56–0.73, p= 0.0042) (Supplementary Figure 1B).
PPV and NPV for the deﬁned cut-off were 41.9% (95% CI=
29.5–55.2%) and 83.1% (95% CI= 71–91.6%), respectively. By
logistic regression analysis, the association between bone








CK-PE DAPI CD45-APC CXCR4-AF488
Fig. 1 CellTracks Analyzer II example images. a Spiked BON1 cells, with no CXCR4 antibody used. b BON1-spiked blood samples run with
CXCR4 antibody. i CXCR4-positive BON1 cell. ii CXCR4-negative BON1 cell. c Clinical validation in patient samples assayed with CXCR4
antibody. i CXCR4-positive CTC in patient ID1. ii CXCR4-negative CTC in patient ID1
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was independent from treatment, grade as well as from the other
sites of metastases.
CXCR4 detection in spiked cells and in CTCs from metastatic NET
patients
Forty patients from Table 1, including 20 patients with bone
metastases and 20 without bone metastatic disease, were further
analysed for CXCR4 expression in CTCs (Table 1, CXCR4 subgroup
analysis). As shown in Table 3, CTCs were detected in 20 (50%)
patients including eight pancreatic, ﬁve bronchial and seven
midgut NETs. Seventeen out of 20 patients with CTCs (85%)
showed a subpopulation expressing CXCR4 (Fig. 1c), including 12
patients with bone metastases (92%) and 5 patients without bone
metastases (71%) (p= 0.21). In those patients with CTC ≥ 1, the
mean percentage of CXCR4+ CTCs was 56% for patients with bone
metastases and 35% for patients without bone disease, respec-
tively (p= 0.18).
Immunohistochemical analysis of CXCR4 expression
Of the 20 patients with detectable CTCs, 14 had blocks of FFPE
tissue available for a further IHC analysis. Staining for CXCR4 was
predominantly nuclear with moderate to strong intensity (Fig. 2a).
Interestingly, patients with G3 and PD tumours had nuclear
Table 1. Clinical characteristics of NET patient samples
All patients Pancreatic Midgut Bronchial
(n= 254) (n= 119) (n= 121) (n= 14)
Age at diagnosis (years)
Median 57 54 60.5 58.5
Range 24–81 24–79 27–81 40–76
Sex
Male 137 (54%) 60 (50%) 69 (57%) 8 (57%)
Female 117 (46%) 59 (50%) 52 (43%) 6 (43%)
Tumour grade
G1 99 (39%) 31 (26%) 66 (54%) 2 (14%)
G2 120 (47%) 65 (55%) 47 (39%) 8 (57%)
G3 33 (13%) 22 (18%) 7 (6%) 4 (29%)
Unknown 2 (1%) 1 (1%) 1 (1%) 0
Metastatic sites
Liver 244 (96%) 118 (99%) 117 (97%) 9 (64%)
Lymph nodes 175 (69%) 68 (57%) 96 (79%) 11 (79%)
Bone 72 (28%) 27 (23%) 36 (30%) 9 (64%)
Lung 24 (9%) 6 (5%) 14 (11%) 4 (29%)
Peritoneum 83 (33%) 16 (13%) 65 (54%) 2 (14%)
Previous treatments
Treatment naive 68 (27%) 35 (29%) 30 (25%) 3 (21%)
On SSAs 74 (29%) 21 (18%) 50 (41%) 3 (21%)
Previous anti-cancer
treatments*
109 (43%) 62 (52%) 39 (32%) 8 (58%)
Unknown 3 (1%) 1 (1%) 2 (2%) 0
CXCR4 subgroup analysis
Primary site 40 15 (38%) 11 (27%) 14 (35%)
Age at diagnosis (years)
Median 57 52 59 59
Range 40–76 43–66 44–73 40–76
Sex
Male 22 (55%) 9 (60%) 5 (45%) 8 (57%)
Female 18 (45%) 6 (40%) 6 (55%) 6 (43%)
Tumour grade
G1 10 (25%) 2 (13%) 6 (55%) 2 (14%)
G2 22 (55%) 10 (67%) 4 (36%) 8 (57%)
G3 8 (20%) 3 (20%) 1 (9%) 4 (29%)
Metastatic sites
Liver 33 (82%) 14 (93%) 10 (91%) 9 (64%)
Lymph nodes 27 (67%) 8 (53%) 8 (73%) 11 (79%)
Bone 20 (50%) 4 (27%) 7 (64%) 9 (64%)
Lung 5 (12%) 0 1 (9%) 4 (29%)
Peritoneum 7 (17%) 2 (13%) 3 (27%) 2 (14%)
Previous treatments
Treatment naive 10 (25%) 6 (40%) 1 (9%) 3 (21%)
On SSAs 10 (25%) 1 (7%) 6 (55%) 3 (21%)
Previous anti-cancer
treatments*
20 (50%) 8 (53%) 4 (36%) 8 (58%)
*Treatments include chemotherapy, radionuclide therapy, targeted therapy,
interferon and liver-directed therapy.
SSA somatostatin analogue, TAE transarterial embolization
Table 2. Association between CTC presence and grade, previous
treatment and sites of metastases
pNETs p Midgut NETs p
(n= 119) (n= 121)




G1 74 26 55 45
G2 63 37 45 55






23 12 19 11








Yes 5 1 5 9




Yes 13 3 31 34




Yes 7 20 10 26




Yes 40 28 45 51
No 36 15 14 11
*Treatments include chemotherapy, radionuclide therapy, targeted therapy,
interferon and liver-directed therapy.
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Table 3. Characteristics of patients with detectable CTCs













1 Pancreas G2 WD 6% Yes 361 141 39 100 100 0
2 Midgut G2 WD 15% Yes 18 6 33 100 40 60
3 Midgut G1 WD < 2% Yes 8 4 50 90 0 90
4 Bronchial G3 PD 50% Yes 1 0 0 80 80 0
5 Bronchial G2 WD 10–12% Yes 179 113 63 100 100 0
6 Midgut G2 WD 1–15% Yes 2 2 100 ND ND ND
7 Bronchial G2 WD 12% Yes 6 3 50 60 50 10
8 Pancreas G2 WD 5% Yes 1 1 100 ND ND ND
9 Midgut G1 WD < 1% Yes 23 21 91 ND ND ND
10 Bronchial G2 WD 8% Yes 78 8 10 20 5 15
11 Midgut G1 WD < 1% Yes 3 2 67 100 100 0
12 Pancreas G3 WD 50% Yes 70 35 50 100 100 0
13 Pancreas G2 WD 12% Yes 4 3 75 100 100 0
14 Midgut G3 PD 80% No 23 7 30 ND ND ND
15 Pancreas G2 WD 4% No 1 0 0 100 100 0
16 Pancreas G2 WD 15% No 4 0 0 80 80 0
17 Pancreas G2 WD 8% No 1 1 100 ND ND ND
18 Pancreas G2 WD 12% No 28 4 14 40 40 0
19 Bronchial G3 WD 25% No 40 11 27 40 40 0
20 Midgut G1 WD < 2% No 42 30 71 ND ND ND
CTC circulating tumour cells, FFPE formalin-ﬁxed parafﬁn-embedded tissue, WD well-differentiated, PD poorly differentiated, ND not done
a b
c d
Fig. 2 Immunohistochemistry for CXCR4 in NET patients. a Strong nuclear CXCR4 expression. b A heterogeneous case showing negative and
nuclear positive cells, with some membrane and dot-like cytoplasmic staining indicated in the inset panel. c Prevalent dot-like cytoplasmic
staining, with focal areas showing a weak cytoplasmic staining. d CXCR4-negative staining
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CXCR4 staining only. One patient with a WD G1 midgut tumour
had only cytoplasmic staining while some cases were hetero-
geneous with both negative and positive cells with nuclear and
cytoplasmic (dot-like or granular) staining (Fig. 2b, c). Figure 2d
shows a CXCR4-negative sample from a patient with no detectable
CTCs, therefore not included in Table 3. There was a trend towards
a signiﬁcant correlation between CXCR4 expression in tumour
tissue and CTCs (rs= 0.48, 95% CI= -0.08, 0.81; p= 0.08, Fig. 3).
DISCUSSION
Bone metastases have been reported in up to 32% of NET
patients2 and are a negative prognostic factor associated with a
median survival of less than 3 years from the diagnosis of bone
lesions.3 Hence, osteotropic NETs may be regarded as an
aggressive subtype, and an understanding of the molecular
mechanisms of osteotropism may inform the development of
therapeutic interventions to reduce skeletal morbidity. In this
study, we investigated the correlation between CTC count and
bone involvement in metastatic NETs and explored the role of the
CXCL12/CXCR4 axis in the biology of bone-colonising NETs.
In keeping with previously published data,14,16 CTCs were
isolated in 43% of metastatic NET patients overall, with a higher
proportion of midgut patients having detectable CTCs compared
with pancreatic patients. A signiﬁcant association was found
between CTC presence and grade, while previous treatments did
not affect CTC count in both pancreatic and midgut NETs. We
showed that CTC presence signiﬁcantly correlates with bone
involvement while there is no association with other metastatic
sites of the disease including lung, peritoneum and lymph nodes.
The high PPV and NPV, particularly for pNETs, suggest that CTCs
could be a predictive marker of bone metastases. Cancer cells are
able to remain as ‘niche-engaged’ dormant cells in the bone
marrow for years before switching to a proliferative phenotype
and eventually causing overt metastases.22 Therefore, CTCs may
be identiﬁed in those patients with subclinical bone metastases
before they become clinically or radiologically manifest. The
association between CTC count by CellSearch and bone metas-
tases has also been reported in patients with prostate,17 breast18
and lung cancer19 although the molecular mechanism has not
been explored.
Here we also investigate potential molecular mechanisms of
bone metastasis in CTCs. The CXCL12/CXCR4 axis is a physiological
mediator of bone marrow homing and quiescence of hemato-
poietic stem cells5 and also regulates the migration of breast and
prostate cancer cells towards tissues with a high-CXCL12
expression including bone.6,7 Based on previous in vitro data
showing that the CXCL12/CXCR4 axis regulates the osteotropism
of NET cancer cells,12 we analysed the expression of CXCR4 on
CTCs in a proportion of our patients and found that it tended to be
higher in patients with bone metastases than in those without it.
Our results did not reach statistical signiﬁcance, likely due to the
small number of patients included in this subgroup analysis, but
the limited sensitivity of imaging to detect subclinical bone
metastases may be another important factor.
Immunohistochemical analysis of CXCR4 expression was in line
with previous studies showing the association between subcel-
lular localisation and advanced and PD tumours,23–25 suggesting a
possible involvement of CXCR4 in the intracellular signalling of
NET cells as a functional nuclear importable receptor, which
requires further investigation at the molecular level. Some degree
of discordance was described between CXCR4 expression on CTCs
and matched FFPE samples. A positive CXCR4 expression was
detected by IHC in three cases that were negative in CTCs, despite
the fact that the same antibody clone was used. There are a
number of explanations that may account for these discrepancies.
First, and most likely, this difference can be explained by sampling
bias as very small numbers of CTCs, ranging from 1 to 4, were
found in the three discordant cases. A second possible reason for
discrepancy, which may be relevant for one of the three
discordant cases, could be that the histology specimen was
obtained 3 years before the CTC sample was taken, and the
reduced CXCR4 expression seen in CTCs might have arisen from
tumour evolution. It has been reported that CXCR4 expression can
be dynamically modulated over the course of the disease in
response to changes in the microenvironment, especially in the
process of tumour-stromal interactions.26 A ﬁnal explanation is the
heterogeneity of expression within tumours and between CTCs,
clearly seen in some of our samples. Our group has already
reported heterogeneity and discordance between biomarker
expression on CTCs and archived tissue as a result of phenotype
changes during CTC translocation from tissue to blood.16
A potential limitation of the study is that the detection of CTCs
was based on EpCAM expression, and this may have missed
subpopulations of EpCAM-negative cells, such as those under-
going EMT. To date, there are no studies demonstrating that EMT
occurs in NET, and the relevance of this putative population is
unclear. Furthermore, recent studies indicate that tumour cell lines
that are arrested in a mesenchymal state by the expression of
EMT-inducing proteins are unable to form overt metastases after
homing in distant organs.27,28 On the contrary, cells with an
intermediate (epithelial and mesenchymal) phenotype, therefore
still detected by the CellSearch system, have the highest plasticity
and metastatic potential,29 thus conﬁrming the importance of
detecting this subgroup of cells.
In conclusion, we have shown a correlation between CTCs
detected by CellSearch and bone metastases, which may inform
clinical investigations and surveillance strategies. Additionally, our
ﬁndings suggest a potential role for CXCR4, which may have
important implications for therapy since CXCR4-directed imaging
modalities30 as well as inhibitors and monoclonal antibodies8,31
are available and are currently being evaluated in NETs.
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